Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.33 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2953350 | 0.77 | SQOR (0.41) | CTSKSOS2CTSS | |
| SCHEMBL14152637 | 0.74 | CNR2 (0.40) | CTSKSOS2CTSSIDH1 | |
| SCHEMBL2955678 | 0.74 | KDM4E (0.39) | SOS2CTSS | |
| SCHEMBL23541640 | 0.74 | ADRB1 (0.50) | IDH1 | |
| SCHEMBL2960932 | 0.74 | CTSK (0.38) | CTSKSOS2CTSSBRS3TRPV4 | |
| SCHEMBL2954296 | 0.71 | SOS2 (0.39) | CTSKSOS2CTSSIDH1 | |
| SCHEMBL30468476 | 0.71 | SOS2 (0.39) | CTSKSOS2CTSSIDH1 | |
| SCHEMBL2958989 | 0.71 | KDM4E (0.42) | SOS2KCNH2 | |
| SCHEMBL2959985 | 0.71 | MAOA (0.45) | CTSKSOS2IDH1 | |
| SCHEMBL26050179 | 0.71 | CTSS (0.41) | CTSKSOS2CTSSBRS3CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | CTSK 4037/4885SOS2 2188/4885CTSS 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.